Physician profile
Jay M Hendler
NPI 1467412171
$17,284.90
in general payments reported to CMS, 2019-2025
39 companies · $907 in 2025
The $907 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,316 · 2020: $4,676 · 2022: $221 · 2023: $1,009 · 2024: $2,155 · 2025: $907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,409 · Travel and Lodging: $1,663.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,408.59 |
| Travel and Lodging | $1,662.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $7,753.65 | 2019-2025 | Ofev |
| Glaxosmithkline, LLC. | $2,933.75 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Grifols USA, LLC | $2,213.87 | 2019-2024 | Prolastin-C Liquid, Xembify |
| Medtronic, INC. | $1,383.98 | 2024 | Illumisite |
| Intuitive Surgical, INC. | $595.33 | 2023-2025 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals Lp | $423.63 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Insmed, INC. | $260.91 | 2019-2025 | Arikayce, Brinsupri |
| Actelion Pharmaceuticals US, INC. | $161.45 | 2019-2024 | Opsumit, Uptravi |
| Verona Pharma, INC. | $126.17 | 2025 | Ohtuvayre |
| United Therapeutics Corporation | $122.50 | 2023-2024 | Tyvaso |
| Pulmonx Corporation | $120.10 | 2019-2020 | |
| Genzyme Corporation | $103.24 | 2019-2024 | |
| Pfizer INC. | $102.51 | 2019-2024 | |
| Amgen INC. | $93.43 | 2023-2025 | Tezspire |
| Merck Sharp & Dohme LLC | $90.18 | 2023-2025 | Zerbaxa, Winrevair |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Hendler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.